略過巡覽連結BioView > 關於我們 > 活動情報 > 近期活動檢視

2018再生醫療研討會

根據Regenerative Medicine 2018研究報告指出,全球再生醫療市場於2017年市場規模為84.6億美元,預測至2021年全球再生醫療市場規模將達224億美元;再生醫療重要發展地區為北美、歐盟及亞太地區,其中以亞太地區成長速度最快,日本因再生醫療法規建置完善及誘導性多功能幹細胞(iPSC)技術已發展成熟,且已有多項臨床試驗進行中,因此成為亞太地區發展再生醫療快速的國家。

活動資訊

我國細胞治療產業在政府政策支持及法規逐漸完善下,因應全球細胞治療發展趨勢,我國廠商已透過與美日公司及學研單位合作,共同發展新興細胞治療產品,且在「細胞治療臨床試驗申請案快審制度」實施,及「特定醫療技術檢查檢驗醫療儀器施行或使用管理辦法」、「再生醫療製劑管理條例(草案)」即將於上路的激勵下,預期將會有多項細胞療法及治療產品上市,嘉惠患者,並促進我國產業升級與發展。
特於2018年9月20日假台北醫學大學舉辦「Forum of Regenerative Medicine 2018」,會中邀請台日兩方業界專家,就「細胞治療」以及「CAR-T及免疫細胞療法」兩大方向進行分享,期在共同努力下促進我國再生醫療產業蓬勃發展,開創利基性再生醫療產品,造福國內大眾。

敬邀各界先進共襄盛舉、踴躍報名參加!


主辦單位:生醫商品化中心、藥品商品化中心、TSPA、臺北醫藥大學
協辦單位:生醫推動方案執行中心、財團法人生物技術開發中心、tfbs
時間:2018/9/20(星期四) 08:00~16:40
地點:臺北醫學大學醫學綜合大學16樓演講廳(台北市信義區吳興街250號)

活動議程

場次 議程內容 主講人
08:00~08:30 Registration
08:30~08:40 Welcome & Opening Remarks/ Group Photo
08:40~09:10 FIRM and its activities under the current regulatory environment in Japan Kunihiko Suzuki, Vice Chairman / FIRM: The Forum for Innovative Regenerative Medicine
09:10~09:30 Development and trends of cell therapy Sunia Wang, Associate Research Fellow / Development Center for Biotechnology- Division of Industrial Information
09:30~10:00 Regulatory considerations on clinical trials of cell therapy and genetically engineered products Hsin-Jung Lee, Senior Medical Reviewer & Researcher / Center for Drug Evaluation
10:00~10:20 Coffee Break
10:20~10:50 Cardiac regeneration using human iPSC derived cardiomyocytes Yoshinori Yoshida, Principal Investigator / (T-CiRA) Takeda-CiRA Joint Program for iPS Cell Applications
10:50~11:20 Development of the iPSC-derived islet like cell product against type 1 diabetes in T-CiRA joint program Taro Toyoda, Principal Investigator/ (T-CiRA)Takeda-CiRA Joint Program for iPS Cell Applications
11:20~11:50 Striving to commercialize regenerative medicine and cell therapy Atsushi Tsuchida, Senior Director/ Sumitomo Dainippon Pharma Co., Ltd.
11:50~12:10 Development of cellular reprogramming and iPSC technology as retinal disease-based platform: From bench to clinic bedside Shih-Hwa Chiou, Section Chair /Taipei Veterans General Hospital
12:10~13:30 Lunch
13:30~14:00 Gene-engineered T cell therapy (CAR-T & TCR-T) in Japan Shuichi Takahashi, Deputy General Manager/ Takara Bio Inc.
14:00~14:20 T cell Immunotherapy against cancers- its evolution and updates Chen-Lung Lin/ Dept of Surgery and Cancer, Imperial College London/ Chair Professor
14:20~14:40 A new paradigm for treating refractory cancers: superCAR-T cell therapy Sareina Chiung-Yuan Wu, CEO/ GenomeFrontier Biosciences, Inc.
14:40~15:00 Application of Immunoprofiling as a predictive biomarker for Immunotherapy to advanced cancer Jan-Mou Lee Ph.D Founder & General Manager/ FullHope Biomedical Co., Ltd.
15:00~15:20 Coffee Break
15:20~15:40 Value-adding strategy for integrated JP-TW biotech investment Brian Po-Hui Chen, Director /Daiwa Corporate Investment (DCI)
15:40~16:00 A novel approach for tolerance induction in transplantation Emi Fukuda, Research Scientist/ Yasuyuki Ishii, Executive Chairman/ REGiMMUNE Co., Ltd
16:00~16:40 Moderator: Dr. Kuan-Der Lee, Taipei Medical University Hospital

報名方式

線上報名
*The organizer reserves the right to make changes in the agenda

報名費用說明

免費參加
(本演講以中文及日文進行,會場備有中日文同步口譯)
(已截止報名)

會員權益常見問題法律聲明網站地圖友站連結服務條款聯絡我們

版權所有©財團法人生物技術開發中心 產業資訊組

地址:115台北市南港區研究院路一段130巷107號E棟 會員專線:(02)7700-3800#5228